BIIB · Biogen

S&P 500 #307 · Nasdaq

Risiko 7/10 · Biotech Turnaround · $205.61 ▲ 2.73%

Kennzahlen

• Price $205.61
• Market cap $30.4B
• P/E (ttm) 22.08
• Div yield none
• 52-wk range $124.56 – $219.72
• Index rank #307 / —

Wichtigste Risiken

• Leqembi (lecanemab) commercial uptake uncertainty (Revenue) — HIGH
• Pipeline clinical failure risk (Valuation) — HIGH
• Biosimilar erosion of MS franchise (Base revenue) — HIGH
• FDA regulatory/reimbursement hurdles for Alzheimer's drugs (Market access) — MED

Fazit

Biogen rebounding on RayThera acquisition and FDA breakthroughs; Alzheimer's franchise execution remains the make-or-break catalyst.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.